SG11202005752PA - Process for the preparation of pyrimidinyl-4-aminopyrazole compounds - Google Patents
Process for the preparation of pyrimidinyl-4-aminopyrazole compoundsInfo
- Publication number
- SG11202005752PA SG11202005752PA SG11202005752PA SG11202005752PA SG11202005752PA SG 11202005752P A SG11202005752P A SG 11202005752PA SG 11202005752P A SG11202005752P A SG 11202005752PA SG 11202005752P A SG11202005752P A SG 11202005752PA SG 11202005752P A SG11202005752P A SG 11202005752PA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrimidinyl
- preparation
- aminopyrazole compounds
- aminopyrazole
- compounds
- Prior art date
Links
- YLLPAAYZOKXPDB-UHFFFAOYSA-N 5-pyrimidin-2-yl-1h-pyrazol-4-amine Chemical class NC1=CNN=C1C1=NC=CC=N1 YLLPAAYZOKXPDB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608398P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/066595 WO2019126383A1 (en) | 2017-12-20 | 2018-12-19 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005752PA true SG11202005752PA (en) | 2020-07-29 |
Family
ID=66994244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005752PA SG11202005752PA (en) | 2017-12-20 | 2018-12-19 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11834438B2 (en) |
| EP (1) | EP3727377B1 (en) |
| JP (1) | JP7284172B2 (en) |
| KR (1) | KR20200100757A (en) |
| CN (1) | CN112088003B (en) |
| AU (1) | AU2018392599A1 (en) |
| BR (1) | BR112020012611A2 (en) |
| CA (1) | CA3086182A1 (en) |
| IL (1) | IL275480B2 (en) |
| MA (1) | MA51339A (en) |
| MX (1) | MX2020006641A (en) |
| SG (1) | SG11202005752PA (en) |
| WO (1) | WO2019126383A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR118641A1 (en) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| CN115894456A (en) * | 2022-11-13 | 2023-04-04 | 药康众拓(江苏)医药科技有限公司 | Deuterated pyrazole aminopyrimidine compound, pharmaceutical composition and application |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| HUE046617T2 (en) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| EP3121173A1 (en) | 2011-11-29 | 2017-01-25 | F. Hoffmann-La Roche AG | Aminopyrimidine derivatives as lrrk2 modulators |
| AR089182A1 (en) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 |
| BR112014011850B1 (en) | 2011-11-29 | 2022-01-11 | Genentech, Inc | AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION |
| BR112014012822A8 (en) | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANTS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 |
| MX363118B (en) | 2012-05-03 | 2019-03-11 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators. |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| US9238644B2 (en) * | 2012-08-17 | 2016-01-19 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| US10829484B2 (en) * | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) * | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| KR20230107407A (en) | 2016-06-16 | 2023-07-14 | 데날리 테라퓨틱스 인크. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3083022A1 (en) | 2017-11-21 | 2019-05-31 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
| AR118641A1 (en) | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
-
2018
- 2018-12-19 EP EP18892459.1A patent/EP3727377B1/en active Active
- 2018-12-19 AU AU2018392599A patent/AU2018392599A1/en active Pending
- 2018-12-19 US US16/955,717 patent/US11834438B2/en active Active
- 2018-12-19 CN CN201880089536.1A patent/CN112088003B/en active Active
- 2018-12-19 MA MA051339A patent/MA51339A/en unknown
- 2018-12-19 BR BR112020012611-0A patent/BR112020012611A2/en unknown
- 2018-12-19 WO PCT/US2018/066595 patent/WO2019126383A1/en unknown
- 2018-12-19 JP JP2020534236A patent/JP7284172B2/en active Active
- 2018-12-19 CA CA3086182A patent/CA3086182A1/en active Pending
- 2018-12-19 MX MX2020006641A patent/MX2020006641A/en unknown
- 2018-12-19 IL IL275480A patent/IL275480B2/en unknown
- 2018-12-19 KR KR1020207020841A patent/KR20200100757A/en not_active Application Discontinuation
- 2018-12-19 SG SG11202005752PA patent/SG11202005752PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727377B1 (en) | 2024-01-31 |
| IL275480B1 (en) | 2023-06-01 |
| IL275480B2 (en) | 2023-10-01 |
| KR20200100757A (en) | 2020-08-26 |
| JP7284172B2 (en) | 2023-05-30 |
| CN112088003B (en) | 2023-10-13 |
| BR112020012611A2 (en) | 2020-12-08 |
| JP2021506892A (en) | 2021-02-22 |
| MX2020006641A (en) | 2021-01-08 |
| US11834438B2 (en) | 2023-12-05 |
| IL275480A (en) | 2020-08-31 |
| CA3086182A1 (en) | 2019-06-27 |
| US20210009566A1 (en) | 2021-01-14 |
| WO2019126383A1 (en) | 2019-06-27 |
| MA51339A (en) | 2020-10-28 |
| CN112088003A (en) | 2020-12-15 |
| AU2018392599A1 (en) | 2020-07-09 |
| EP3727377A4 (en) | 2021-08-18 |
| EP3727377A1 (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276917A (en) | Process for the preparation of elobixibat | |
| SI3433285T1 (en) | An improved process for the preparation of sugammadex | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| GB2593352B (en) | Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone) | |
| IL266589A (en) | Process for the preparation of umeclidinium bromide | |
| LT3765440T (en) | Process for the preparation of n-alkyl-nitratoethylnitramines | |
| IL248267B (en) | Process for the preparation of substituted cycloserines | |
| IL281254A (en) | Process for the preparation of lenvatinib | |
| IL275480A (en) | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| IL268835B (en) | Process for the preparation of 2-cyanoimidazole compounds | |
| IL260070B (en) | Method for the preparation of substituted 2-aryl-ethanols | |
| IL275381A (en) | A process for the preparation of crisaborole | |
| EP3877361C0 (en) | Process for the preparation of arylsulfonylpropenenitriles | |
| PL3599256T3 (en) | Process for the preparation of polyorganosiloaxnes | |
| IL262889B (en) | Process for the manufacture of 6-alkynyl-pyridine derivatives | |
| HUE053496T2 (en) | Process for the preparation of isocyanates | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| IL274560A (en) | Process for the preparation of raltegravir | |
| HK1252354A1 (en) | Process for the preparation of amphiphilic imidazolinium compounds | |
| IL253562A0 (en) | Process for the preparation of triazoles | |
| GB201713146D0 (en) | Process for the preparation of glycidol | |
| GB201708375D0 (en) | Process for the preparation of glycidol |